ASCVD

7 · 20 / page

Ask MedXY AI

Latest news

Tag

CardiologyLDL-CASCVD

Digitally Enabled QI Intervention Modestly Improves LDL-C Control in ASCVD: SAPPHIRE-LDL Trial

By MedXY|Jul 25, 2026

A cluster RCT in Brazil found that a digitally enabled quality improvement intervention modestly reduced LDL-C and increased treatment intensification in ASCVD patients, but a care gap remained.

CardiologyASCVDGLP-1 receptor agonists

ASCVD

Latest news

Digitally Enabled QI Intervention Modestly Improves LDL-C Control in ASCVD: SAPPHIRE-LDL Trial

Semaglutide Drives Vascular Regeneration: The SEMA-VR CardioLink-15 Trial Reveals a Shift in Progenitor Cell Flux

The Silent Genetic Threat: Why Most Patients with Familial Hypercholesterolemia Are Still Falling Through the Clinical Cracks

The Hidden Burden of Heart and Brain Health: ASCVD Linked to Significantly Elevated Suicide Risk

High BMI, High Benefit: How PCSK9 Inhibition Optimizes Outcomes in Obese Patients with ASCVD

Calprotectin: A Mechanistically Informed Biomarker for Predicting Atherosclerotic Cardiovascular Disease

Evaluating AHA PREVENT Equations and Lipoprotein(a) in Cardiovascular Risk Stratification: Integrative Insights from MESA and UK Biobank Cohorts